Incyte

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. 

CEO
William J. Meury
CEOWilliam J. Meury
Employees
2,844
Employees2,844
Headquarters
Wilmington, Delaware
HeadquartersWilmington, Delaware
Founded
1991
Founded1991
Employees
2,844
Employees2,844

INCY Key Statistics

Market cap
25.89B
Market cap25.89B
Price-Earnings ratio
16.33
Price-Earnings ratio16.33
Dividend yield
Dividend yield
Average volume
1.16M
Average volume1.16M
High today
High today
Low today
Low today
Open price
$126.89
Open price$126.89
Volume
0.00
Volume0.00
52 Week high
$132.60
52 Week high$132.60
52 Week low
$81.09
52 Week low$81.09

Stock Snapshot

The current Incyte(INCY) stock price is $127.74, with a market capitalization of 25.89B. The stock trades at a price-to-earnings (P/E) ratio of 16.33.

On 2026-08-28, Incyte(INCY) stock opened at $126.89, reached a high of —, and a low of —.

The Incyte(INCY)'s current trading volume is 0, compared to an average daily volume of 1.16M.

In the last year, Incyte(INCY) shares hit a 52-week high of $132.60 and a 52-week low of $81.09.

In the last year, Incyte(INCY) shares hit a 52-week high of $132.60 and a 52-week low of $81.09.

INCY News

Investing.com 23h
Incyte stock price target maintained at $150 by H.C. Wainwright - Investing.com

...

Incyte stock price target maintained at $150 by H.C. Wainwright - Investing.com
TipRanks 1d
Buy Rating Reaffirmed on Incyte as ‘734 Pancreatic Cancer Data Looms; 12-Month Price Target Reiterated at $150

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Incyte today and set a price target of $150.00. Mitchell Kapoor has given his Buy rating due...

Simply Wall St 7d
Incyte Nears Fair Value, Is The Upside Already Priced In?

Incyte (INCY) has drawn investor attention after its recent share price move, with the stock last closing at $127.22. The shift comes against a backdrop of mixe...

Incyte Nears Fair Value, Is The Upside Already Priced In?

Analyst ratings

52%

of 31 ratings
Buy
41.9%
Hold
51.6%
Sell
6.5%

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.